16 June 2021
e-therapeutics plc
Results of Annual General Meeting
Issue of Equity and Total Voting Rights
e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company") is pleased to announce that all resolutions were duly passed by shareholders of the Company at the Annual General Meeting held earlier today.
Results of the voting on each resolution will shortly be available on the Company's website at www.etherapeutics.co.uk.
Accordingly, pursuant to the Fundraise announced on 14 May 2021, an application has been made for, in aggregate, 93,750,000 new Ordinary Shares to be admitted to trading on AIM which is expected to occur at 8.00 a.m. on 17 June 2021. The new Ordinary Shares comprise 81,208,333 Placing Shares, 8,708,334 Subscription Shares and 3,833,333 Retail Shares.
Total Voting Rights
Following the issue of the Placing Shares, Subscription Shares and Retail Shares, the Company will have 514,523,546 Ordinary Shares of 0.1 pence each in issue. The Company does not hold any Ordinary Shares in treasury. The figure of 514,523,546 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Defined terms in this announcement shall have the same meaning as in the Launch Announcement dated 13 May 2021 unless otherwise specified.
Enquiries:
| e-therapeutics plc | |
| Ali Mortazavi, CEO Karl Keegan, CFO
| Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk |
| | |
| SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
| Nominated Adviser and Broker | |
| Matthew Johnson/Caroline Rowe (Corporate Finance) | |
| Vadim Alexandre/Rob Rees (Corporate Broking) | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
